MGC026
Multiple Solid Tumors
Phase 1Active
Key Facts
About MacroGenics
MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop and commercialize life-changing, antibody-based cancer medicines. Its strategy is built upon a suite of proprietary technology platforms that generate a diverse pipeline of novel bispecific antibodies and ADCs, both for proprietary development and strategic partnerships. The company has advanced multiple candidates into clinical trials, retains economic rights to several partnered/commercialized assets, and maintains in-house GMP manufacturing capabilities to control its development destiny.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-401 | Calidi Biotherapeutics | IND-Enabling |
| Abexinostat + Pembrolizumab | Xynomic Pharmaceuticals | Phase 1b |
| Early Cancer Detection Platform | Astrin Biosciences | Pre-clinical |
| ABC (²¹²Pb-undisclosed) | ARTBIO | Discovery |
| UNO (Ultrahigh NO) | Beyond Air | Phase 1/2 |
| SonoLeukin™ | Vesselon | Pre-clinical |
| ELEPHAS-04 (Mayo Clinic) | Elephas Biosciences | Observational |
| Metastasis Companion Diagnostic | Mestastop Solutions | Prospective Clinical Trials |
| Anti-metastasis Drug Discovery | Mestastop Solutions | Preclinical/Discovery |
| Zimberelimab (AB122) | Arcus Biosciences | Phase 3 |
| ORIC-101 | ORIC Pharmaceuticals | Phase 1b |
| MGC028 | MacroGenics | Phase 1 |